Venetoclax-based regimens in combination with trametinib for RAS-mutated relapsed or refractory myeloid malignancies
- 16 April 2022
- journal article
- letter
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 57 (6) , 1034-1037
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AMLBlood Advances, 2021
- Outcomes of relapsed or refractory acute myeloid leukemia patients failing venetoclax‐based salvage therapiesEuropean Journal of Haematology, 2020
- Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemiaNature Cancer, 2020
- Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimensHaematologica, 2020
- Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AMLBlood, 2020
- Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II StudyClinical Lymphoma Myeloma and Leukemia, 2019
- Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia modelsHaematologica, 2019
- Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid LeukemiaClinical Lymphoma Myeloma and Leukemia, 2019
- Therapeutic strategies to target RAS-mutant cancersNature Reviews Clinical Oncology, 2018
- Activity of the oral mitogen‐activated protein kinase kinase inhibitor trametinib in RAS‐mutant relapsed or refractory myeloid malignanciesCancer, 2016